{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:43:46Z","timestamp":1792122226708,"version":"4.4.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04735-5","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:04:24Z","timestamp":1772172264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers"],"prefix":"10.1007","volume":"17","author":[{"given":"Mustafa T.","family":"Ardah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-5783","authenticated-orcid":false,"given":"Waleed K.","family":"Abdulsahib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihsan Khudhair","family":"Jasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Malathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeepta Sekhar","family":"Patro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Alex","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashna","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakhrijakhon","family":"Aminqulov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"3","key":"4735_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290\u20136.","journal-title":"Immunol Cell Biol"},{"key":"4735_CR2","doi-asserted-by":"crossref","unstructured":"Nwaogwugwua CJ, Nnaemeka J, Wilborn S, Abdelwahed S. Holistic understanding of the current landscape, challenges, and potential advancements in the integration of immunotherapy with traditional cancer treatments. A narrative review; 2025.","DOI":"10.20944\/preprints202506.2378.v1"},{"issue":"2","key":"4735_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02280-7","volume":"41","author":"NR Raghani","year":"2024","unstructured":"Raghani NR, Chorawala MR, Mahadik M, Patel RB, Prajapati BG, Parekh PS. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies. Med Oncol. 2024;41(2):51.","journal-title":"Med Oncol"},{"issue":"6","key":"4735_CR4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4062\/biomolther.2024.146","volume":"32","author":"SM Choi","year":"2024","unstructured":"Choi SM, Lee JH, Ko S, Hong SS, Jin HE. Mechanism of action and pharmacokinetics of approved bispecific antibodies. Biomol Ther (Seoul). 2024;32(6):708\u201322.","journal-title":"Biomol Ther (Seoul)"},{"issue":"2","key":"4735_CR5","first-page":"12","volume":"2","author":"SE Udeabor","year":"2024","unstructured":"Udeabor SE. Monoclonal antibodies in modern medicine: their therapeutic potential and future directions. Trends Pharmacol Sci. 2024;2(2):12\u201320.","journal-title":"Trends Pharmacol Sci"},{"key":"4735_CR6","doi-asserted-by":"crossref","unstructured":"Kothari M, Wanjari A, Acharya S, Karwa V, Chavhan R, Kumar S et al. A comprehensive review of monoclonal antibodies in modern medicine: Tracing the evolution of a revolutionary therapeutic approach. Cureus. 2024;16(6).","DOI":"10.7759\/cureus.61983"},{"key":"4735_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/antib14010016","author":"H In","year":"2025","unstructured":"In H, Park M, Lee H, Han KH. Immune cell engagers: advancing precision immunotherapy for cancer treatment. Antibodies. 2025. https:\/\/doi.org\/10.3390\/antib14010016.","journal-title":"Antibodies"},{"issue":"1","key":"4735_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/antib14010016","volume":"14","author":"H In","year":"2025","unstructured":"In H, Park M, Lee H, Han KH. Immune cell engagers: advancing precision immunotherapy for cancer treatment. Antibodies. 2025;14(1):16.","journal-title":"Antibodies"},{"key":"4735_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184550","author":"MH Omer","year":"2023","unstructured":"Omer MH, Shafqat A, Ahmad O, Alkattan K, Yaqinuddin A, Damlaj M. Bispecific antibodies in hematological malignancies: a scoping review. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15184550.","journal-title":"Cancers (Basel)"},{"issue":"22","key":"4735_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223776","volume":"16","author":"J Molldrem","year":"2024","unstructured":"Molldrem J, Zha D. Unlocking intracellular oncology targets: the unique role of antibody-based T-cell receptor mimic (TCRm) therapeutics in T-cell engagers (TCEs) and antibody-drug conjugates (ADCs). Cancers. 2024;16(22):3776.","journal-title":"Cancers"},{"issue":"11","key":"4735_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111820","volume":"17","author":"W-A Kwon","year":"2025","unstructured":"Kwon W-A, Joung JY. T-cell engager therapy in prostate cancer: molecular insights into a new frontier in immunotherapy. Cancers. 2025;17(11):1820.","journal-title":"Cancers"},{"issue":"19 Suppl","key":"4735_CR12","first-page":"S1","volume":"21","author":"A STAFF","year":"2015","unstructured":"STAFF A, Committee S. Cancer progress report. Clin Cancer Res. 2015;21(19 Suppl):S1.","journal-title":"Clin Cancer Res"},{"key":"4735_CR13","unstructured":"Glatt DM. Monoclonal antibody-mediated tumor targeting and drug delivery to solid tumors. The University of North Carolina at Chapel Hill; 2016."},{"issue":"3","key":"4735_CR14","doi-asserted-by":"publisher","first-page":"e010760","DOI":"10.1136\/jitc-2024-010760","volume":"13","author":"TU Marron","year":"2025","unstructured":"Marron TU, Luke JJ, Hoffner B, Perlmutter J, Szczepanek C, Anagnostou V, et al. A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy. J Immunother Cancer. 2025;13(3):e010760.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4735_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2356820","volume":"25","author":"J Palecki","year":"2024","unstructured":"Palecki J, Bhasin A, Bernstein A, Mille PJ, Tester WJ, Kelly WK, et al. T-cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer. Cancer Biol Ther. 2024;25(1):2356820.","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"4735_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.it.2017.04.004","volume":"38","author":"EK Curran","year":"2017","unstructured":"Curran EK, Godfrey J, Kline J. Mechanisms of immune tolerance in leukemia and lymphoma. Trends Immunol. 2017;38(7):513\u201325.","journal-title":"Trends Immunol"},{"issue":"1","key":"4735_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01521-5","volume":"8","author":"L Tang","year":"2023","unstructured":"Tang L, Huang Z, Mei H, Hu Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Ther. 2023;8(1):306.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"4735_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061188","volume":"13","author":"I-T Chyuan","year":"2021","unstructured":"Chyuan I-T, Chu C-L, Hsu P-N. Targeting the tumor microenvironment for improving therapeutic effectiveness in cancer immunotherapy: focusing on immune checkpoint inhibitors and combination therapies. Cancers. 2021;13(6):1188.","journal-title":"Cancers"},{"issue":"6545","key":"4735_CR19","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.abg1209","volume":"372","author":"U Brinkmann","year":"2021","unstructured":"Brinkmann U, Kontermann RE. Bispecific antibodies. Science. 2021;372(6545):916\u20137.","journal-title":"Science"},{"issue":"7","key":"4735_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","volume":"21","author":"C Rolin","year":"2024","unstructured":"Rolin C, Zimmer J, Seguin-Devaux C. Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases. Cell Mol Immunol. 2024;21(7):643\u201361.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"4735_CR21","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cpt.1961","volume":"108","author":"A Betts","year":"2020","unstructured":"Betts A, van der Graaf PH. Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology. Clin Pharmacol Ther. 2020;108(3):528\u201341.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"4735_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102402","volume":"15","author":"DT Abdeldaim","year":"2023","unstructured":"Abdeldaim DT, Schindowski K. Fc-engineered therapeutic antibodies: recent advances and future directions. Pharmaceutics. 2023;15(10):2402.","journal-title":"Pharmaceutics"},{"key":"4735_CR23","doi-asserted-by":"crossref","unstructured":"Amash A, Volkers G, Farber P, Griffin D, Davison KS, Goodman A, et al. editors. Developability considerations for bispecific and multispecific antibodies. Taylor & Francis; 2024. MAbs.","DOI":"10.1080\/19420862.2024.2394229"},{"issue":"1","key":"4735_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00332-6","volume":"9","author":"Y Asaadi","year":"2021","unstructured":"Asaadi Y, Jouneghani FF, Janani S, Rahbarizadeh F. A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomarker Res. 2021;9(1):87.","journal-title":"Biomarker Res"},{"issue":"4","key":"4735_CR25","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cpt.1396","volume":"106","author":"J Duell","year":"2019","unstructured":"Duell J, Lammers PE, Djuretic I, Chunyk AG, Alekar S, Jacobs I, et al. Bispecific antibodies in the treatment of hematologic malignancies. Clin Pharmacol Ther. 2019;106(4):781\u201391.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4735_CR26","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.7150\/thno.81494","volume":"13","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo A, Compte M, \u00c1lvarez-Vallina L, Sanz L. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy. Theranostics. 2023;13(3):1028.","journal-title":"Theranostics"},{"issue":"11","key":"4735_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ph14111172","volume":"14","author":"D Kamakura","year":"2021","unstructured":"Kamakura D, Asano R, Yasunaga M. T cell bispecific antibodies: an antibody-based delivery system for inducing antitumor immunity. Pharmaceuticals. 2021;14(11):1172.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"4735_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","volume":"16","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo A, \u00c1lvarez-Vallina L, Sanz L. Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023;16(1):83.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"4735_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","volume":"13","author":"DG Guy","year":"2018","unstructured":"Guy DG, Uy GL. Bispecific antibodies for the treatment of acute myeloid leukemia. Curr Hematol Malig Rep. 2018;13(6):417\u201325.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"4735_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s13287-022-03169-4","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhong M, Zhong W, Lan Y, Yuan Z, Duan Y, et al. Construction of tandem diabody (IL-6\/CD20)-secreting human umbilical cord mesenchymal stem cells and its experimental treatment on diffuse large B cell lymphoma. Stem Cell Res Ther. 2022;13(1):473.","journal-title":"Stem Cell Res Ther"},{"issue":"11","key":"4735_CR31","doi-asserted-by":"publisher","first-page":"5632","DOI":"10.3390\/ijms22115632","volume":"22","author":"M Elshiaty","year":"2021","unstructured":"Elshiaty M, Schindler H, Christopoulos P. Principles and current clinical landscape of multispecific antibodies against cancer. Int J Mol Sci. 2021;22(11):5632.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4735_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70191","volume":"6","author":"R Qiao","year":"2025","unstructured":"Qiao R, Liu Y, Mao Q, Li J, Lu Y, Shi J, et al. Novel trispecific neutralizing antibodies with enhanced potency and breadth against pan-sarbecoviruses. MedComm (2020). 2025;6(5):e70191.","journal-title":"MedComm (2020)"},{"key":"4735_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1170042","volume":"14","author":"J Harwardt","year":"2023","unstructured":"Harwardt J, Carrara SC, Bogen JP, Schoenfeld K, Grzeschik J, Hock B, et al. Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody. Front Immunol. 2023;14:1170042.","journal-title":"Front Immunol"},{"issue":"1","key":"4735_CR34","first-page":"37","volume":"7","author":"D Keri","year":"2024","unstructured":"Keri D, Walker M, Singh I, Nishikawa K, Garces F. Next generation of multispecific antibody engineering. Antib Ther. 2024;7(1):37\u201352.","journal-title":"Antib Ther"},{"issue":"4","key":"4735_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044176","volume":"24","author":"H Tang","year":"2023","unstructured":"Tang H, Gao Y, Han J. Application progress of the single domain antibody in medicine. Int J Mol Sci. 2023;24(4):4176.","journal-title":"Int J Mol Sci"},{"key":"4735_CR36","doi-asserted-by":"crossref","unstructured":"Brennan FR, Polli JR, Sathish J, Ramones M, Wolf B, Schlothauer T, et al. editors. Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies. Taylor & Francis; 2025. mAbs.","DOI":"10.1080\/19420862.2025.2505092"},{"issue":"1","key":"4735_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","volume":"23","author":"M Metkar","year":"2024","unstructured":"Metkar M, Pepin CS, Moore MJ. Tailor made: the art of therapeutic mRNA design. Nat Rev Drug Discov. 2024;23(1):67\u201383.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"4735_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tibtech.2014.03.001","volume":"32","author":"T De Meyer","year":"2014","unstructured":"De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as research and diagnostic tools. Trends Biotechnol. 2014;32(5):263\u201370.","journal-title":"Trends Biotechnol"},{"issue":"3","key":"4735_CR39","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1021\/acscentsci.2c01437","volume":"9","author":"F Thoreau","year":"2023","unstructured":"Thoreau F, Szijj PA, Greene MK, Rochet LN, Thanasi IA, Blayney JK, et al. Modular chemical construction of IgG-like mono-and bispecific synthetic antibodies (SynAbs). ACS Cent Sci. 2023;9(3):476\u201387.","journal-title":"ACS Cent Sci"},{"issue":"2","key":"4735_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1039\/D1CB00082A","volume":"3","author":"F Thoreau","year":"2022","unstructured":"Thoreau F, Chudasama V. Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. RSC Chem Biol. 2022;3(2):140\u201369.","journal-title":"RSC Chem Biol"},{"issue":"2","key":"4735_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1208\/s12248-019-0402-2","volume":"22","author":"W Yang","year":"2020","unstructured":"Yang W, Gadgil P, Krishnamurthy VR, Landis M, Mallick P, Patel D, et al. The evolving druggability and developability space: chemically modified new modalities and emerging small molecules. AAPS J. 2020;22(2):21.","journal-title":"AAPS J"},{"issue":"12","key":"4735_CR42","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41573-024-01051-x","volume":"23","author":"PJ Carter","year":"2024","unstructured":"Carter PJ, Quarmby V. Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics. Nat Rev Drug Discov. 2024;23(12):898\u2013913.","journal-title":"Nat Rev Drug Discov"},{"key":"4735_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/9781394182862.ch2","volume-title":"Polypharmacology: Strategies for Multi\u2010Target Drug Discovery","author":"EA Blomme","year":"2025","unstructured":"Blomme EA, Green JR, Mahalingaiah PKS, Van Vleet TR, Vo A. The Safety Relevance and Interpretation of Compound Off-target Interactions. In: Polypharmacology: Strategies for Multi\u2010Target Drug Discovery. 2025. p. 9\u201324."},{"key":"4735_CR44","doi-asserted-by":"crossref","unstructured":"Cunningham O, Scott M, Zhou ZS, Finlay WJ, editors. Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns. Taylor & Francis; 2021. MAbs.","DOI":"10.1080\/19420862.2021.1999195"},{"key":"4735_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061243","author":"C Ord\u00f3\u00f1ez-Reyes","year":"2022","unstructured":"Ord\u00f3\u00f1ez-Reyes C, Garcia-Robledo JE, Chamorro DF, Mosquera A, Sussmann L, Ruiz-Pati\u00f1o A, et al. Bispecific antibodies in cancer immunotherapy: a novel response to an old question. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14061243.","journal-title":"Pharmaceutics"},{"issue":"7","key":"4735_CR46","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","volume":"24","author":"A Fenis","year":"2024","unstructured":"Fenis A, Demaria O, Gauthier L, Vivier E, Narni-Mancinelli E. New immune cell engagers for cancer immunotherapy. Nat Rev Immunol. 2024;24(7):471\u201386.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"4735_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102824","volume":"15","author":"M Shanshal","year":"2023","unstructured":"Shanshal M, Caimi PF, Adjei AA, Ma WW. T-cell engagers in solid cancers\u2014current landscape and future directions. Cancers. 2023;15(10):2824.","journal-title":"Cancers"},{"issue":"1","key":"4735_CR48","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-025-02332-6","volume":"10","author":"Z Chao","year":"2025","unstructured":"Chao Z, Mei Q, Yang C, Luo J, Liu P, Peng H, et al. Immunological synapse: structures, molecular mechanisms and therapeutic implications in disease. Signal Transduct Target Ther. 2025;10(1):254.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4735_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010132","volume":"15","author":"C Carrasco-Padilla","year":"2022","unstructured":"Carrasco-Padilla C, Hernaiz-Esteban A, \u00c1lvarez-Vallina L, Aguilar-Sope\u00f1a O, Roda-Navarro P. Bispecific antibody format and the organization of immunological synapses in T cell-redirecting strategies for cancer immunotherapy. Pharmaceutics. 2022;15(1):132.","journal-title":"Pharmaceutics"},{"issue":"23","key":"4735_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21238984","volume":"21","author":"K Eddy","year":"2020","unstructured":"Eddy K, Chen S. Overcoming immune evasion in melanoma. Int J Mol Sci. 2020;21(23):8984.","journal-title":"Int J Mol Sci"},{"key":"4735_CR51","doi-asserted-by":"crossref","unstructured":"Fine J, Meksiriporn B, Tan J, Spangler JB. Mechanism-driven design of multispecific antibodies for targeted disease treatment. Annual Rev Chem Biomol Eng. 2024;15.","DOI":"10.1146\/annurev-chembioeng-100522-102155"},{"issue":"6","key":"4735_CR52","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","volume":"22","author":"M Labrie","year":"2022","unstructured":"Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer. 2022;22(6):323\u201339.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"4735_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","volume":"24","author":"BC Cho","year":"2023","unstructured":"Cho BC, Simi A, Sabari J, Vijayaraghavan S, Moores S, Spira A. Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. Clin Lung Cancer. 2023;24(2):89\u201397.","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"4735_CR54","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/14712598.2022.2072209","volume":"22","author":"RP Chen","year":"2022","unstructured":"Chen RP, Shinoda K, Rampuria P, Jin F, Bartholomew T, Zhao C, et al. Bispecific antibodies for immune cell retargeting against cancer. Expert Opin Biol Ther. 2022;22(8):965\u201382.","journal-title":"Expert Opin Biol Ther"},{"key":"4735_CR55","doi-asserted-by":"crossref","unstructured":"Grant J, Hua F, Apgar JF, Burke JM, Marcantonio DH, editors. Mechanistic PK\/PD modeling to address early-stage biotherapeutic dosing feasibility questions. Taylor & Francis; 2023. MAbs.","DOI":"10.1080\/19420862.2023.2192251"},{"issue":"4","key":"4735_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041189","volume":"15","author":"AP Menon","year":"2023","unstructured":"Menon AP, Moreno B, Meraviglia-Crivelli D, Nonatelli F, Villanueva H, Barainka M, et al. Modulating T cell responses by targeting CD3. Cancers. 2023;15(4):1189.","journal-title":"Cancers"},{"key":"4735_CR57","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fcell.2019.00370","volume":"7","author":"P Roda-Navarro","year":"2020","unstructured":"Roda-Navarro P, \u00c1lvarez-Vallina L. Understanding the spatial topology of artificial immunological synapses assembled in T cell-redirecting strategies: a major issue in cancer immunotherapy. Front Cell Dev Biol. 2020;7:370.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"4735_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010405","volume":"23","author":"E Guerra","year":"2021","unstructured":"Guerra E, Di Pietro R, Basile M, Trerotola M, Alberti S. Cancer-homing CAR-T cells and endogenous immune population dynamics. Int J Mol Sci. 2021;23(1):405.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4735_CR59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"4735_CR60","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s44222-023-00030-y","volume":"1","author":"J Deckers","year":"2023","unstructured":"Deckers J, Anbergen T, Hokke AM, de Dreu A, Schrijver DP, de Bruin K, et al. Engineering cytokine therapeutics. Nat Rev Bioeng. 2023;1(4):286\u2013303.","journal-title":"Nat Rev Bioeng"},{"issue":"3","key":"4735_CR61","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H, et al. Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience. Transplantation Cell therapy. 2024;30(3):308. e1-. e13.","journal-title":"Transplantation Cell therapy"},{"issue":"5","key":"4735_CR62","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1080\/10428194.2024.2446617","volume":"66","author":"G Varma","year":"2025","unstructured":"Varma G, Fogel L, Gordon B, Saldarriaga MM, Ahn J, Aleman A, et al. Real-world safety and efficacy of teclistamab in relapsed\/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis. Leuk Lymphoma. 2025;66(5):942\u201351.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"4735_CR63","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367.","journal-title":"Nat Med"},{"key":"4735_CR64","doi-asserted-by":"crossref","unstructured":"Rodriguez Valdes C, Voorhees PM, D\u2019Souza A, Chung A, Tuchman S, Safah H, et al. Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). American Society of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.7531"},{"key":"4735_CR65","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-2-4","author":"O Castaneda-Puglianini","year":"2021","unstructured":"Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin\u2019s lymphomas and multiple myeloma. Drugs Context. 2021. https:\/\/doi.org\/10.7573\/dic.2021-2-4.","journal-title":"Drugs Context"},{"issue":"12","key":"4735_CR66","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1007\/s00262-023-03559-4","volume":"72","author":"ML Del Giudice","year":"2023","unstructured":"Del Giudice ML, Galimberti S, Buda G. Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents. Cancer Immunol Immunother. 2023;72(12):3931\u20137.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"4735_CR67","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ejh.14353","volume":"114","author":"C Labanca","year":"2025","unstructured":"Labanca C, Martino EA, Vigna E, Bruzzese A, Mendicino F, Lucia E, et al. Talquetamab in multiple myeloma: efficacy, safety, and future directions. Eur J Haematol. 2025;114(3):386\u201399.","journal-title":"Eur J Haematol"},{"issue":"11","key":"4735_CR68","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1080\/17474086.2020.1831380","volume":"13","author":"G Chitadze","year":"2020","unstructured":"Chitadze G, Laqua A, Lettau M, Baldus CD, Br\u00fcggemann M. Bispecific antibodies in acute lymphoblastic leukemia therapy. Expert Rev Hematol. 2020;13(11):1211\u201333.","journal-title":"Expert Rev Hematol"},{"issue":"14","key":"4735_CR69","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522\u201331.","journal-title":"Blood"},{"issue":"7","key":"4735_CR70","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2024025454","volume":"145","author":"LH Sehn","year":"2025","unstructured":"Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u2265\u20092 prior therapies. Blood. 2025;145(7):708\u201319.","journal-title":"Blood"},{"issue":"16suppl","key":"4735_CR71","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"AL Garfall","year":"2024","unstructured":"Garfall AL, Nooka AK, van de Donk N, Moreau P, Bhutani M, Oriol A, et al. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42(16suppl):7540.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4735_CR72","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","volume":"141","author":"L Falchi","year":"2023","unstructured":"Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141(5):467\u201380.","journal-title":"Blood"},{"issue":"18","key":"4735_CR73","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.3390\/cancers15184550","volume":"15","author":"MH Omer","year":"2023","unstructured":"Omer MH, Shafqat A, Ahmad O, Alkattan K, Yaqinuddin A, Damlaj M. Bispecific antibodies in hematological malignancies: a scoping review. Cancers. 2023;15(18):4550.","journal-title":"Cancers"},{"issue":"1","key":"4735_CR74","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020;183(1):126\u201342. e17.","journal-title":"Cell"},{"key":"4735_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1566202","volume":"15","author":"W Cao","year":"2025","unstructured":"Cao W, Ma S, Han L, Xing H, Li Y, Jiang Z, et al. Bispecific antibodies in immunotherapy for acute leukemia: latest updates from the 66th annual meeting of the American society of hematology, 2024. Front Oncol. 2025;15:1566202.","journal-title":"Front Oncol"},{"issue":"6","key":"4735_CR76","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","volume":"16","author":"M Larrosa-Garcia","year":"2017","unstructured":"Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther. 2017;16(6):991\u20131001.","journal-title":"Mol Cancer Ther"},{"key":"4735_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.605766","volume":"12","author":"Y-L Zhao","year":"2021","unstructured":"Zhao Y-L, Liu D-Y, Sun R-J, Zhang J-P, Zhou J-R, Wei Z-J, et al. Integrating CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-cell or chemotherapy-based complete remission in B-cell acute lymphoblastic leukemia. Front Immunol. 2021;12:605766.","journal-title":"Front Immunol"},{"key":"4735_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061819","author":"D Swan","year":"2023","unstructured":"Swan D, Murphy P, Glavey S, Quinn J. Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15061819.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4735_CR79","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1097\/HS9.0000000000000547","volume":"5","author":"M Gavriatopoulou","year":"2021","unstructured":"Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Terpos E, Dimopoulos MA. SARS-CoV-2 vaccines in patients with multiple myeloma. Hemasphere. 2021;5(3):e547.","journal-title":"Hemasphere"},{"issue":"1","key":"4735_CR80","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1182\/hematology.2020000110","volume":"2020","author":"G Lancman","year":"2020","unstructured":"Lancman G, Richter J, Chari A. Bispecifics, trispecifics, and other novel immune treatments in myeloma. Hematol Am Soc Hematol Educ Program. 2020;2020(1):264\u201371.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"4735_CR81","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathmechdis-032221-115501","volume":"17","author":"L Maiorino","year":"2022","unstructured":"Maiorino L, Da\u00dfler-Plenker J, Sun L, Egeblad M. Innate immunity and cancer pathophysiology. Annu Rev Pathol. 2022;17:425\u201357.","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"4735_CR82","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2256904","volume":"19","author":"T Huan","year":"2023","unstructured":"Huan T, Guan B, Li H, Tu X, Zhang C, Tang B. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer. Hum Vaccin Immunother. 2023;19(2):2256904.","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"4735_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70046","volume":"14","author":"A Zhu","year":"2024","unstructured":"Zhu A, Bai Y, Nan Y, Ju D. Natural killer cell engagers: from bi-specific to tri\u2010specific and tetra\u2010specific engagers for enhanced cancer immunotherapy. Clin Transl Med. 2024;14(11):e70046.","journal-title":"Clin Transl Med"},{"key":"4735_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002883","author":"K Hurov","year":"2021","unstructured":"Hurov K, Lahdenranta J, Upadhyaya P, Haines E, Cohen H, Repash E, et al. BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist\u2122 (Bicycle TICA\u2122) induces tumor localized CD137 agonism. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002883.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4735_CR85","doi-asserted-by":"publisher","first-page":"e001408","DOI":"10.1136\/jitc-2020-001408","volume":"8","author":"M Lecoultre","year":"2020","unstructured":"Lecoultre M, Dutoit V, Walker PR. Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review. J Immunother Cancer. 2020;8(2):e001408.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4735_CR86","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1208\/s12248-023-00845-y","volume":"25","author":"Y Wang","year":"2023","unstructured":"Wang Y, Barrett A, Hu Q. Targeting macrophages for tumor therapy. AAPS J. 2023;25(5):80.","journal-title":"AAPS J"},{"key":"4735_CR87","doi-asserted-by":"crossref","unstructured":"Sallman DA, Donnellan WB, Asch AS, Lee DJ, Al Malki M, Marcucci G, et al. The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results. American Society of Clinical Oncology; 2019.","DOI":"10.1097\/01.HS9.0000561792.92005.b1"},{"key":"4735_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.635173","volume":"12","author":"S Chen","year":"2021","unstructured":"Chen S, Lai SWT, Brown CE, Feng M. Harnessing and enhancing macrophage phagocytosis for cancer therapy. Front Immunol. 2021;12:635173.","journal-title":"Front Immunol"},{"issue":"5","key":"4735_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/biology13050307","volume":"13","author":"A Mitra","year":"2024","unstructured":"Mitra A, Kumar A, Amdare NP, Pathak R. Current landscape of cancer immunotherapy: harnessing the immune arsenal to overcome immune evasion. Biology. 2024;13(5):307.","journal-title":"Biology"},{"issue":"1","key":"4735_CR90","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","volume":"13","author":"N Zhang","year":"2023","unstructured":"Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13(1):82.","journal-title":"Blood Cancer J"},{"key":"4735_CR91","unstructured":"Horowitz NB. Engineering a Robust and Scalable Platforn for the Production of IEILC1-Like Nk Cells, a Novel Solid Tumor Immunothereapeutic Modality. Stanford University; 2022."},{"key":"4735_CR92","doi-asserted-by":"crossref","unstructured":"Madsen AV, Kristensen P, Buell AK, Goletz S, editors. Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats. Taylor & Francis; 2023. MAbs.","DOI":"10.1080\/19420862.2023.2189432"},{"issue":"1","key":"4735_CR93","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/bjd.17918","volume":"182","author":"A Kimball","year":"2020","unstructured":"Kimball A, Kerbusch T, van Aarle F, Kulkarni P, Li Q, Blauvelt A, et al. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. Br J Dermatol. 2020;182(1):180\u20139.","journal-title":"Br J Dermatol"},{"issue":"1","key":"4735_CR94","doi-asserted-by":"publisher","first-page":"fcab309","DOI":"10.1093\/braincomms\/fcab309","volume":"4","author":"LD Faulhaber","year":"2022","unstructured":"Faulhaber LD, Phuong AQ, Hartsuyker KJ, Cho Y, Mand KK, Harper SD, et al. Brain capillary obstruction during neurotoxicity in a mouse model of anti-CD19 chimeric antigen receptor T-cell therapy. Brain Commun. 2022;4(1):fcab309.","journal-title":"Brain Commun"},{"issue":"5","key":"4735_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052514","volume":"22","author":"M Vizovisek","year":"2021","unstructured":"Vizovisek M, Ristanovic D, Menghini S, Christiansen MG, Schuerle S. The tumor proteolytic landscape: a challenging frontier in cancer diagnosis and therapy. Int J Mol Sci. 2021;22(5):2514.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4735_CR96","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","volume":"31","author":"KK Radtke","year":"2025","unstructured":"Radtke KK, Bender BC, Li Z, Turner DC, Roy S, Belousov A, et al. Clinical pharmacology of cytokine release syndrome with T-cell-engaging bispecific antibodies: current insights and drug development strategies. Clin Cancer Res. 2025;31(2):245\u201357.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4735_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1576","volume":"14","author":"T Gu","year":"2022","unstructured":"Gu T, Hu K, Si X, Hu Y, Huang H. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR\u2010T treatment. WIREs mechanisms of disease. 2022;14(6):e1576.","journal-title":"WIREs mechanisms of disease"},{"issue":"20","key":"4735_CR98","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How i treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141(20):2430\u201342.","journal-title":"Blood"},{"issue":"6","key":"4735_CR99","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.anai.2021.08.413","volume":"127","author":"KS Tuano","year":"2021","unstructured":"Tuano KS, Seth N, Chinen J. Secondary immunodeficiencies: an overview. Ann Allergy Asthma Immunol. 2021;127(6):617\u201326.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"4735_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9071477","volume":"9","author":"ML Minardi","year":"2021","unstructured":"Minardi ML, Fato I, Di Gennaro F, Mosti S, Mastrobattista A, Cerva C, et al. Common and rare hematological manifestations and adverse drug events during treatment of active TB: a state of art. Microorganisms. 2021;9(7):1477.","journal-title":"Microorganisms"},{"issue":"8","key":"4735_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00716-3","volume":"12","author":"H Chen","year":"2022","unstructured":"Chen H, Yu T, Lin L, Xing L, Cho S-F, Wen K, et al. \u03b3-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 2022;12(8):118.","journal-title":"Blood Cancer J"},{"issue":"1","key":"4735_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"key":"4735_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107097","volume":"89","author":"S He","year":"2020","unstructured":"He S, Xu J, Wu J. The emerging role of co-stimulatory molecules and their agonistic mAb-based combination therapies in melanoma. Int Immunopharmacol. 2020;89:107097.","journal-title":"Int Immunopharmacol"},{"key":"4735_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1200941","volume":"14","author":"A Shafqat","year":"2023","unstructured":"Shafqat A, Omer MH, Ahmed EN, Mushtaq A, Ijaz E, Ahmed Z, et al. Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy. Front Immunol. 2023;14:1200941.","journal-title":"Front Immunol"},{"issue":"6","key":"4735_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061535","volume":"9","author":"AS Poltavets","year":"2020","unstructured":"Poltavets AS, Vishnyakova PA, Elchaninov AV, Sukhikh GT, Fatkhudinov TK. Macrophage modification strategies for efficient cell therapy. Cells. 2020;9(6):1535.","journal-title":"Cells"},{"issue":"9","key":"4735_CR106","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915\u20139.","journal-title":"Cancer Discov"},{"issue":"1","key":"4735_CR107","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2514040","volume":"14","author":"K Pojar","year":"2025","unstructured":"Pojar K, Reckendorfer D, Strauss J, Szaffich S, Ahmadi-Erber S, Schippers T, et al. Combining local cytokine delivery and systemic immunization with recombinant artLCMV boosts antitumor efficacy in several preclinical tumor models. Oncoimmunology. 2025;14(1):2514040.","journal-title":"Oncoimmunology"},{"issue":"4","key":"4735_CR108","doi-asserted-by":"publisher","first-page":"283","DOI":"10.36401\/JIPO-24-23","volume":"7","author":"CDH Lopes","year":"2024","unstructured":"Lopes CDH, Braganca Xavier C, Torrado C, Veneziani AC, Megid TBC. A comprehensive exploration of agents targeting tumor microenvironment: challenges and future perspectives. J Immunotherapy Precision Oncol. 2024;7(4):283\u201399.","journal-title":"J Immunotherapy Precision Oncol"},{"key":"4735_CR109","doi-asserted-by":"publisher","DOI":"10.1039\/D3TB03044J","author":"S Liu","year":"2024","unstructured":"Liu S, Guo H, Li D, Wang C. Immunologically effective biomaterials enhance immunotherapy of prostate cancer. J Mater Chem B. 2024. https:\/\/doi.org\/10.1039\/D3TB03044J.","journal-title":"J Mater Chem B"},{"key":"4735_CR110","doi-asserted-by":"crossref","unstructured":"Bergamaschi C, Gaspar M, Ciucci T, Sitnikova SI, Cayatte C, Pica M, et al. editors. Innovative strategies for T cell engagers for cancer immunotherapy. Taylor & Francis; 2025. mAbs.","DOI":"10.1080\/19420862.2025.2531223"},{"issue":"9","key":"4735_CR111","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202100040","volume":"4","author":"A Shahryari","year":"2021","unstructured":"Shahryari A, Burtscher I, Nazari Z, Lickert H. Engineering gene therapy: advances and barriers. Adv Ther. 2021;4(9):2100040.","journal-title":"Adv Ther"},{"issue":"12","key":"4735_CR112","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.tips.2024.10.005","volume":"45","author":"V Blay","year":"2024","unstructured":"Blay V, Pandiella A. Strategies to boost antibody selectivity in oncology. Trends Pharmacol Sci. 2024;45(12):1135\u201349.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"4735_CR113","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2077898","volume":"11","author":"A Petrazzuolo","year":"2022","unstructured":"Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, Kepp O. Trial watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. Oncoimmunology. 2022;11(1):2077898.","journal-title":"Oncoimmunology"},{"issue":"12","key":"4735_CR114","doi-asserted-by":"publisher","first-page":"7782","DOI":"10.1021\/acs.chemrev.2c00915","volume":"123","author":"L Qian","year":"2023","unstructured":"Qian L, Lin X, Gao X, Khan RU, Liao J-Y, Du S, et al. The dawn of a new era: targeting the \u201cundruggables\u201d with antibody-based therapeutics. Chem Rev. 2023;123(12):7782\u2013853.","journal-title":"Chem Rev"},{"issue":"1","key":"4735_CR115","first-page":"1","volume":"10","author":"UH Weidle","year":"2013","unstructured":"Weidle UH, Tiefenthaler G, Weiss EH, Georges G, Brinkmann U. The intriguing options of multispecific antibody formats for treatment of cancer. Cancer Genomics Proteomics. 2013;10(1):1\u201318.","journal-title":"Cancer Genomics Proteomics"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04735-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04735-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04735-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:04:33Z","timestamp":1775225073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04735-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4735"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04735-5","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"531"}}